Sight Sciences (SGHT)

• Market cap: $158M
• 1 day: -3.17%
• 5 days: -4.69%
• 1 month: 27.08%
• 3 months: 2.69%
• 6 months: -42.34%
• Year to date: -14.80%
• 1 year: -45.05%
• 5 years: -90.90%
• 10 years: -90.90%
• Sector: Healthcare
• Industry: Medical Devices

About: Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Employees: 216

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

8,633% more call options, than puts

Call options by funds: $262K | Put options by funds: $3K

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

10.46% more ownership

Funds ownership: 34.09% [Q3] → 44.54% (+10.46%) [Q4]

5% more funds holding

Funds holding: 78 [Q3] → 82 (+4) [Q4]

4% more capital invested

Capital invested by funds: $108M [Q3] → $112M (+$3.92M) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 18% downside
• Avg. target: $3.25 7% upside
• High target: $4 31% upside

4 analyst ratings

• positive: 1 25%
• neutral: 3 75%
• negative: 0 0%

Lake Street Frank Takkinen 19% 1-year accuracy 4 / 21 met price target	18% downside $2.50	Hold Maintained	6 Mar 2025
Stifel Thomas Stephan 33% 1-year accuracy 4 / 12 met price target	31% upside $4	Buy Maintained	6 Mar 2025
Piper Sandler Matt O'Brien 40% 1-year accuracy 20 / 50 met price target	15% upside $3.50	Neutral Maintained	6 Mar 2025
Citigroup Joanne Wuensch 45% 1-year accuracy 18 / 40 met price target	2% downside $3	Neutral Maintained	4 Mar 2025